Andrew Chantry

2.5k total citations
60 papers, 1.3k citations indexed

About

Andrew Chantry is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Andrew Chantry has authored 60 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 29 papers in Hematology and 17 papers in Molecular Biology. Recurrent topics in Andrew Chantry's work include Multiple Myeloma Research and Treatments (25 papers), Bone health and treatments (18 papers) and Peptidase Inhibition and Analysis (8 papers). Andrew Chantry is often cited by papers focused on Multiple Myeloma Research and Treatments (25 papers), Bone health and treatments (18 papers) and Peptidase Inhibition and Analysis (8 papers). Andrew Chantry collaborates with scholars based in United Kingdom, United States and Belgium. Andrew Chantry's co-authors include Michelle A. Lawson, Peter I. Croucher, John A. Snowden, Holly Evans, Karin Vanderkerken, Clive Buckle, John D. Shaughnessy, David R. Stover, D Heath and Julia Paton‐Hough and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Andrew Chantry

58 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Chantry United Kingdom 18 691 603 578 166 109 60 1.3k
Catherine Williams United Kingdom 15 556 0.8× 497 0.8× 540 0.9× 67 0.4× 104 1.0× 31 1.0k
Ya‐Wei Qiang United States 16 685 1.0× 620 1.0× 1.1k 1.8× 63 0.4× 109 1.0× 35 1.6k
Denise Toscani Italy 18 557 0.8× 570 0.9× 571 1.0× 51 0.3× 108 1.0× 48 1.2k
Marı́a Jesús Moro Spain 16 368 0.5× 761 1.3× 576 1.0× 42 0.3× 266 2.4× 26 1.1k
Kirsten van Lom Netherlands 25 326 0.5× 579 1.0× 539 0.9× 136 0.8× 427 3.9× 47 1.5k
Takashi Taga Japan 20 220 0.3× 675 1.1× 637 1.1× 58 0.3× 279 2.6× 114 1.5k
P. Kostakis Australia 9 385 0.6× 212 0.4× 437 0.8× 27 0.2× 91 0.8× 11 842
Ana M. Ortiz Spain 19 168 0.2× 164 0.3× 347 0.6× 60 0.4× 76 0.7× 50 1.0k
Manuel J. Del Rey Spain 18 254 0.4× 150 0.2× 320 0.6× 99 0.6× 92 0.8× 49 1.2k
Simon N. Robinson United States 22 511 0.7× 589 1.0× 378 0.7× 74 0.4× 443 4.1× 66 1.5k

Countries citing papers authored by Andrew Chantry

Since Specialization
Citations

This map shows the geographic impact of Andrew Chantry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Chantry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Chantry more than expected).

Fields of papers citing papers by Andrew Chantry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Chantry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Chantry. The network helps show where Andrew Chantry may publish in the future.

Co-authorship network of co-authors of Andrew Chantry

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Chantry. A scholar is included among the top collaborators of Andrew Chantry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Chantry. Andrew Chantry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tazzyman, Simon, Yidan Sun, Darren Lath, et al.. (2025). An oncolytic adenovirus targeting SLAMF7 demonstrates anti-myeloma efficacy. Leukemia. 39(6). 1449–1463.
2.
Tazzyman, Simon, Darren Lath, Joe Conner, et al.. (2023). HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models. Viruses. 15(3). 603–603. 4 indexed citations
3.
Dillon, Richard, et al.. (2023). Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study. Blood Advances. 7(14). 3686–3694. 9 indexed citations
4.
Chantry, Andrew, et al.. (2021). The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma. Cancers. 13(22). 5687–5687. 6 indexed citations
5.
Brown, Janet E., et al.. (2021). Myeloma Bone Disease: The Osteoblast in the Spotlight. Journal of Clinical Medicine. 10(17). 3973–3973. 8 indexed citations
6.
Green, Alanna C., Darren Lath, Brant Walkley, et al.. (2019). TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. Journal of Bone and Mineral Research. 34(12). 2311–2326. 17 indexed citations
7.
Chantry, Andrew, et al.. (2019). A university – Led initiative to promote voluntary non-remunerated blood donation in a developing country. Transfusion and Apheresis Science. 58(5). 674–679. 6 indexed citations
8.
Lath, Darren, Clive Buckle, Holly Evans, et al.. (2018). ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. PLoS ONE. 13(6). e0199517–e0199517. 10 indexed citations
9.
Chantry, Andrew, et al.. (2017). SAHA-induced TRAIL-sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture. Experimental Cell Research. 360(2). 226–235. 14 indexed citations
10.
Green, Alanna C., et al.. (2017). Mesenchymal lineage cells and their importance in B lymphocyte niches. Bone. 119. 42–56. 12 indexed citations
11.
Paton‐Hough, Julia, Andrew Chantry, & Michelle A. Lawson. (2015). A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease. Bone. 77. 57–68. 31 indexed citations
12.
Talley, P., et al.. (2015). Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma. British Medical Bulletin. 113(1). 15–30. 17 indexed citations
13.
Lawson, Michelle A., Julia Paton‐Hough, Holly Evans, et al.. (2015). NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. PLoS ONE. 10(3). e0119546–e0119546. 29 indexed citations
14.
15.
16.
Chantry, Andrew, Aaron W. Mulivor, Marc Baud’huin, et al.. (2010). Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of Bone and Mineral Research. 25(12). 2633–2646. 112 indexed citations
17.
Cairney, Claire J., Guido Sanguinetti, Andrew Chantry, et al.. (2009). A systems biology approach to Down syndrome: Identification of Notch/Wnt dysregulation in a model of stem cells aging. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1792(4). 353–363. 37 indexed citations
18.
Edwards, Claire M., Anke J. Roelofs, Andrew Chantry, et al.. (2007). Apomine™, an inhibitor of HMG‐CoA‐reductase, promotes apoptosis of myeloma cellsin vitroand is associated with a modulation of myelomain vivo. International Journal of Cancer. 120(8). 1657–1663. 17 indexed citations
19.
Chantry, Andrew, John A. Snowden, Charles Craddock, et al.. (2006). Long-Term Outcomes of Myeloablation and Autologous Transplantation of Relapsed Acute Myeloid Leukemia in Second Remission: A British Society of Blood and Marrow Transplantation Registry Study. Biology of Blood and Marrow Transplantation. 12(12). 1310–1317. 11 indexed citations
20.
Chantry, Andrew, et al.. (1999). Overexpression of ErbB2 impairs ligand-dependent downregulation of epidermal growth factor receptors via a post-transcriptional mechanism. Journal of Cellular Biochemistry. 74(1). 23–30. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Williams Breakdown of academic impact, for papers by Ya‐Wei Qiang Breakdown of academic impact, for papers by Denise Toscani Breakdown of academic impact, for papers by Marı́a Jesús Moro Breakdown of academic impact, for papers by Kirsten van Lom Breakdown of academic impact, for papers by Takashi Taga Breakdown of academic impact, for papers by P. Kostakis Breakdown of academic impact, for papers by Ana M. Ortiz Breakdown of academic impact, for papers by Manuel J. Del Rey Breakdown of academic impact, for papers by Simon N. Robinson
Rankless by CCL
2026